Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Posidonia oceanica extract (POE) is a polyphenol-rich hydrophilic/ethanolic extract derived from the leaves of the Mediterranean seagrass *Posidonia oceanica*. The phytocomplex primarily consists of catechins (approximately 88%), alongside gallic acid, ferulic acid, and other phenolic compounds. Preclinical research, largely conducted by the University of Florence, suggests therapeutic potential in inflammatory pain, various cancers (fibrosarcoma, breast, and hepatocellular carcinoma), and metabolic disorders like diabetes and non-alcoholic fatty liver disease (NAFLD). Its mechanism of action involves the inhibition of matrix metalloproteinases (MMP-2 and MMP-9), suppression of the NF-κB signaling pathway, and modulation of autophagy, which collectively contribute to its anti-inflammatory, anti-invasive, and metabolic regulatory properties.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on posidonia oceanica extract.